Wednesday Apr 16
GlycoMimetics Reports Presentation of Data on Rivipansel (GMI-1070)...
GlycoMimetics Reports Presentation of Data on Rivipansel in Combination with Current FDA-Approved Treatment for Sickle Cell Disease announced that data for its lead clinical drug candidate, rivipansel , was highlighted via one oral presentation and one poster at the 8th Annual According to a release, rivipansel is in clinical trials as a potential ... (more)
GlycoMimetics Announces Presentation of Data on Rivipansel (GMI-1070) ...
Rivipansel is in clinical trials as a potential therapy for the treatment of vaso-occlusive crisis in people with sickle cell disease.
GlycoMimetics: A Promising Sickle Cell Disease Play
GlycoMimetics' GMI-1070 is a first-in-class pan-selectin inhibitor that could shorten sickle cell disease vaso-occlusive crisis, and has the potential for more than 1 billion peak sales.
Medical News Today
Guidelines on the management of pulmonary hypertension of sickle cell disease
The American Thoracic Society has developed clinical practice guidelines to help clinicians identify and manage patients with sickle cell disease who are at increased risk for mortality from pulmonary hypertension .